CN115227806A - 原纤维蛋白-2重组蛋白在制备预防或治疗原纤维蛋白-2缺陷型眼病的产品中的用途 - Google Patents
原纤维蛋白-2重组蛋白在制备预防或治疗原纤维蛋白-2缺陷型眼病的产品中的用途 Download PDFInfo
- Publication number
- CN115227806A CN115227806A CN202110969727.0A CN202110969727A CN115227806A CN 115227806 A CN115227806 A CN 115227806A CN 202110969727 A CN202110969727 A CN 202110969727A CN 115227806 A CN115227806 A CN 115227806A
- Authority
- CN
- China
- Prior art keywords
- fbn2
- group
- protein
- aav
- compared
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 238000011282 treatment Methods 0.000 title claims abstract description 20
- 230000002950 deficient Effects 0.000 title claims abstract description 19
- 230000002265 prevention Effects 0.000 title claims abstract description 8
- 238000002360 preparation method Methods 0.000 title description 4
- 208000022873 Ocular disease Diseases 0.000 title description 2
- 108090000623 proteins and genes Proteins 0.000 claims abstract description 36
- 102000007056 Recombinant Fusion Proteins Human genes 0.000 claims abstract description 35
- 108010008281 Recombinant Fusion Proteins Proteins 0.000 claims abstract description 35
- 108010030242 Fibrillin-2 Proteins 0.000 claims abstract description 16
- 208000030533 eye disease Diseases 0.000 claims abstract description 15
- 238000004519 manufacturing process Methods 0.000 claims abstract description 3
- 239000007924 injection Substances 0.000 claims description 65
- 238000002347 injection Methods 0.000 claims description 65
- 230000014509 gene expression Effects 0.000 claims description 38
- 102000004169 proteins and genes Human genes 0.000 claims description 28
- 239000000243 solution Substances 0.000 claims description 18
- 108020004999 messenger RNA Proteins 0.000 claims description 14
- 230000002207 retinal effect Effects 0.000 claims description 13
- 208000017442 Retinal disease Diseases 0.000 claims description 12
- 239000003814 drug Substances 0.000 claims description 12
- 206010038923 Retinopathy Diseases 0.000 claims description 11
- 230000001225 therapeutic effect Effects 0.000 claims description 11
- 230000004044 response Effects 0.000 claims description 10
- 208000002780 macular degeneration Diseases 0.000 claims description 8
- 239000000203 mixture Substances 0.000 claims description 8
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 6
- 229940079593 drug Drugs 0.000 claims description 5
- 239000003085 diluting agent Substances 0.000 claims description 4
- 230000004323 axial length Effects 0.000 claims description 3
- 229940124531 pharmaceutical excipient Drugs 0.000 claims description 3
- 239000000725 suspension Substances 0.000 claims description 3
- 206010010356 Congenital anomaly Diseases 0.000 claims description 2
- 239000004480 active ingredient Substances 0.000 claims description 2
- 230000004329 axial myopia Effects 0.000 claims description 2
- 239000003795 chemical substances by application Substances 0.000 claims description 2
- 239000000839 emulsion Substances 0.000 claims description 2
- 239000000796 flavoring agent Substances 0.000 claims description 2
- 235000013355 food flavoring agent Nutrition 0.000 claims description 2
- 235000003599 food sweetener Nutrition 0.000 claims description 2
- 238000009472 formulation Methods 0.000 claims description 2
- 230000001105 regulatory effect Effects 0.000 claims description 2
- 239000003765 sweetening agent Substances 0.000 claims description 2
- 239000006188 syrup Substances 0.000 claims description 2
- 235000020357 syrup Nutrition 0.000 claims description 2
- 229960005486 vaccine Drugs 0.000 claims description 2
- 102000005868 Fibrillin-2 Human genes 0.000 claims 6
- 102100031510 Fibrillin-2 Human genes 0.000 abstract description 277
- 101000846890 Homo sapiens Fibrillin-2 Proteins 0.000 abstract description 270
- 101100119834 Homo sapiens FBN2 gene Proteins 0.000 abstract description 31
- 238000000034 method Methods 0.000 abstract description 10
- 238000011160 research Methods 0.000 abstract description 10
- 239000013598 vector Substances 0.000 abstract description 9
- 230000007547 defect Effects 0.000 abstract description 8
- 230000000694 effects Effects 0.000 abstract description 6
- 201000010099 disease Diseases 0.000 abstract description 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract description 4
- 238000012217 deletion Methods 0.000 abstract description 2
- 230000037430 deletion Effects 0.000 abstract description 2
- 238000010172 mouse model Methods 0.000 abstract description 2
- 239000013642 negative control Substances 0.000 description 132
- 239000002609 medium Substances 0.000 description 50
- 210000001508 eye Anatomy 0.000 description 25
- 230000008859 change Effects 0.000 description 21
- 239000007788 liquid Substances 0.000 description 18
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 14
- 210000001525 retina Anatomy 0.000 description 13
- 239000000523 sample Substances 0.000 description 13
- 101100119835 Mus musculus Fbn2 gene Proteins 0.000 description 11
- 241000699670 Mus sp. Species 0.000 description 11
- 239000000047 product Substances 0.000 description 11
- 241000699666 Mus <mouse, genus> Species 0.000 description 10
- 238000001514 detection method Methods 0.000 description 10
- 238000002571 electroretinography Methods 0.000 description 10
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 9
- 238000001962 electrophoresis Methods 0.000 description 9
- 238000002474 experimental method Methods 0.000 description 9
- 239000013049 sediment Substances 0.000 description 9
- 210000001519 tissue Anatomy 0.000 description 9
- 238000005406 washing Methods 0.000 description 9
- 206010002091 Anaesthesia Diseases 0.000 description 8
- 230000037005 anaesthesia Effects 0.000 description 8
- 239000006180 TBST buffer Substances 0.000 description 7
- 241000700605 Viruses Species 0.000 description 7
- 238000001949 anaesthesia Methods 0.000 description 7
- 238000002156 mixing Methods 0.000 description 7
- 238000007789 sealing Methods 0.000 description 7
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 6
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 6
- 206010064930 age-related macular degeneration Diseases 0.000 description 6
- 238000006243 chemical reaction Methods 0.000 description 6
- 230000000052 comparative effect Effects 0.000 description 6
- 239000012528 membrane Substances 0.000 description 6
- 238000012014 optical coherence tomography Methods 0.000 description 6
- QGMRQYFBGABWDR-UHFFFAOYSA-M Pentobarbital sodium Chemical compound [Na+].CCCC(C)C1(CC)C(=O)NC(=O)[N-]C1=O QGMRQYFBGABWDR-UHFFFAOYSA-M 0.000 description 5
- 230000015572 biosynthetic process Effects 0.000 description 5
- 210000004027 cell Anatomy 0.000 description 5
- 238000005520 cutting process Methods 0.000 description 5
- 239000003889 eye drop Substances 0.000 description 5
- 239000011521 glass Substances 0.000 description 5
- 239000003292 glue Substances 0.000 description 5
- 239000006228 supernatant Substances 0.000 description 5
- GSDSWSVVBLHKDQ-UHFFFAOYSA-N 9-fluoro-3-methyl-10-(4-methylpiperazin-1-yl)-7-oxo-2,3-dihydro-7H-[1,4]oxazino[2,3,4-ij]quinoline-6-carboxylic acid Chemical compound FC1=CC(C(C(C(O)=O)=C2)=O)=C3N2C(C)COC3=C1N1CCN(C)CC1 GSDSWSVVBLHKDQ-UHFFFAOYSA-N 0.000 description 4
- 102000007469 Actins Human genes 0.000 description 4
- 108010085238 Actins Proteins 0.000 description 4
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 4
- ROOXNKNUYICQNP-UHFFFAOYSA-N ammonium peroxydisulfate Substances [NH4+].[NH4+].[O-]S(=O)(=O)OOS([O-])(=O)=O ROOXNKNUYICQNP-UHFFFAOYSA-N 0.000 description 4
- 229910001870 ammonium persulfate Inorganic materials 0.000 description 4
- 210000004087 cornea Anatomy 0.000 description 4
- 230000004300 dark adaptation Effects 0.000 description 4
- 229940012356 eye drops Drugs 0.000 description 4
- 229960001699 ofloxacin Drugs 0.000 description 4
- 238000012546 transfer Methods 0.000 description 4
- 108020004414 DNA Proteins 0.000 description 3
- 102000053602 DNA Human genes 0.000 description 3
- 206010064571 Gene mutation Diseases 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- 108091034117 Oligonucleotide Proteins 0.000 description 3
- 239000013614 RNA sample Substances 0.000 description 3
- 102000006382 Ribonucleases Human genes 0.000 description 3
- 108010083644 Ribonucleases Proteins 0.000 description 3
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 3
- 239000000872 buffer Substances 0.000 description 3
- 239000003153 chemical reaction reagent Substances 0.000 description 3
- 238000004140 cleaning Methods 0.000 description 3
- 238000007865 diluting Methods 0.000 description 3
- 239000012153 distilled water Substances 0.000 description 3
- 230000009368 gene silencing by RNA Effects 0.000 description 3
- 229910052757 nitrogen Inorganic materials 0.000 description 3
- 238000002577 ophthalmoscopy Methods 0.000 description 3
- 229960002275 pentobarbital sodium Drugs 0.000 description 3
- 210000001747 pupil Anatomy 0.000 description 3
- 230000009467 reduction Effects 0.000 description 3
- 238000005070 sampling Methods 0.000 description 3
- 238000002791 soaking Methods 0.000 description 3
- 239000011550 stock solution Substances 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- CPKVUHPKYQGHMW-UHFFFAOYSA-N 1-ethenylpyrrolidin-2-one;molecular iodine Chemical compound II.C=CN1CCCC1=O CPKVUHPKYQGHMW-UHFFFAOYSA-N 0.000 description 2
- 238000011746 C57BL/6J (JAX™ mouse strain) Methods 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 2
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- KWYHDKDOAIKMQN-UHFFFAOYSA-N N,N,N',N'-tetramethylethylenediamine Chemical compound CN(C)CCN(C)C KWYHDKDOAIKMQN-UHFFFAOYSA-N 0.000 description 2
- 239000002033 PVDF binder Substances 0.000 description 2
- 229920000153 Povidone-iodine Polymers 0.000 description 2
- 210000000683 abdominal cavity Anatomy 0.000 description 2
- VAZSKTXWXKYQJF-UHFFFAOYSA-N ammonium persulfate Chemical compound [NH4+].[NH4+].[O-]S(=O)OOS([O-])=O VAZSKTXWXKYQJF-UHFFFAOYSA-N 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 238000007664 blowing Methods 0.000 description 2
- 238000010276 construction Methods 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 230000018109 developmental process Effects 0.000 description 2
- 238000001035 drying Methods 0.000 description 2
- 208000033530 early-onset macular degeneration Diseases 0.000 description 2
- 238000000605 extraction Methods 0.000 description 2
- 239000003885 eye ointment Substances 0.000 description 2
- 238000011049 filling Methods 0.000 description 2
- 238000000227 grinding Methods 0.000 description 2
- 239000001963 growth medium Substances 0.000 description 2
- 239000007928 intraperitoneal injection Substances 0.000 description 2
- 238000003475 lamination Methods 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- 229910052751 metal Inorganic materials 0.000 description 2
- 239000002184 metal Substances 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 208000001491 myopia Diseases 0.000 description 2
- 230000004379 myopia Effects 0.000 description 2
- 229920002981 polyvinylidene fluoride Polymers 0.000 description 2
- 229960001621 povidone-iodine Drugs 0.000 description 2
- 238000003757 reverse transcription PCR Methods 0.000 description 2
- FSYKKLYZXJSNPZ-UHFFFAOYSA-N sarcosine Chemical compound C[NH2+]CC([O-])=O FSYKKLYZXJSNPZ-UHFFFAOYSA-N 0.000 description 2
- 238000000926 separation method Methods 0.000 description 2
- HDTRYLNUVZCQOY-UHFFFAOYSA-N α-D-glucopyranosyl-α-D-glucopyranoside Natural products OC1C(O)C(O)C(CO)OC1OC1C(O)C(O)C(O)C(CO)O1 HDTRYLNUVZCQOY-UHFFFAOYSA-N 0.000 description 1
- 239000013607 AAV vector Substances 0.000 description 1
- HRPVXLWXLXDGHG-UHFFFAOYSA-N Acrylamide Chemical compound NC(=O)C=C HRPVXLWXLXDGHG-UHFFFAOYSA-N 0.000 description 1
- OEYHNRIKHFQBCG-UHFFFAOYSA-N C(C=C)(=O)N.[Mg] Chemical compound C(C=C)(=O)N.[Mg] OEYHNRIKHFQBCG-UHFFFAOYSA-N 0.000 description 1
- 208000002177 Cataract Diseases 0.000 description 1
- 229920000742 Cotton Polymers 0.000 description 1
- 241000702421 Dependoparvovirus Species 0.000 description 1
- SNRUBQQJIBEYMU-UHFFFAOYSA-N Dodecane Natural products CCCCCCCCCCCC SNRUBQQJIBEYMU-UHFFFAOYSA-N 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- 238000002965 ELISA Methods 0.000 description 1
- 238000012286 ELISA Assay Methods 0.000 description 1
- 102000016942 Elastin Human genes 0.000 description 1
- 108010014258 Elastin Proteins 0.000 description 1
- 241000588724 Escherichia coli Species 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 102100034343 Integrase Human genes 0.000 description 1
- 102000011931 Nucleoproteins Human genes 0.000 description 1
- 108010061100 Nucleoproteins Proteins 0.000 description 1
- 206010033296 Overdoses Diseases 0.000 description 1
- 108010026552 Proteome Proteins 0.000 description 1
- 238000012228 RNA interference-mediated gene silencing Methods 0.000 description 1
- 108010092799 RNA-directed DNA polymerase Proteins 0.000 description 1
- 239000008156 Ringer's lactate solution Substances 0.000 description 1
- CGNLCCVKSWNSDG-UHFFFAOYSA-N SYBR Green I Chemical compound CN(C)CCCN(CCC)C1=CC(C=C2N(C3=CC=CC=C3S2)C)=C2C=CC=CC2=[N+]1C1=CC=CC=C1 CGNLCCVKSWNSDG-UHFFFAOYSA-N 0.000 description 1
- 108010077895 Sarcosine Proteins 0.000 description 1
- 108020004682 Single-Stranded DNA Proteins 0.000 description 1
- 108700019146 Transgenes Proteins 0.000 description 1
- HDTRYLNUVZCQOY-WSWWMNSNSA-N Trehalose Natural products O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-WSWWMNSNSA-N 0.000 description 1
- 239000007983 Tris buffer Substances 0.000 description 1
- 102000005789 Vascular Endothelial Growth Factors Human genes 0.000 description 1
- 108010019530 Vascular Endothelial Growth Factors Proteins 0.000 description 1
- 239000002250 absorbent Substances 0.000 description 1
- 230000002745 absorbent Effects 0.000 description 1
- 230000006978 adaptation Effects 0.000 description 1
- 125000003275 alpha amino acid group Chemical group 0.000 description 1
- HDTRYLNUVZCQOY-LIZSDCNHSA-N alpha,alpha-trehalose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-LIZSDCNHSA-N 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 238000000137 annealing Methods 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 208000021018 autosomal dominant inheritance Diseases 0.000 description 1
- 238000010009 beating Methods 0.000 description 1
- 238000005452 bending Methods 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 229960000074 biopharmaceutical Drugs 0.000 description 1
- 238000009835 boiling Methods 0.000 description 1
- 230000001680 brushing effect Effects 0.000 description 1
- 210000005252 bulbus oculi Anatomy 0.000 description 1
- 238000010804 cDNA synthesis Methods 0.000 description 1
- BMLSTPRTEKLIPM-UHFFFAOYSA-I calcium;potassium;disodium;hydrogen carbonate;dichloride;dihydroxide;hydrate Chemical compound O.[OH-].[OH-].[Na+].[Na+].[Cl-].[Cl-].[K+].[Ca+2].OC([O-])=O BMLSTPRTEKLIPM-UHFFFAOYSA-I 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 238000003759 clinical diagnosis Methods 0.000 description 1
- 239000002299 complementary DNA Substances 0.000 description 1
- 238000013329 compounding Methods 0.000 description 1
- 210000000795 conjunctiva Anatomy 0.000 description 1
- 210000002808 connective tissue Anatomy 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 238000004925 denaturation Methods 0.000 description 1
- 230000036425 denaturation Effects 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 230000010339 dilation Effects 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 238000007598 dipping method Methods 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 125000003438 dodecyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 235000013601 eggs Nutrition 0.000 description 1
- 210000004177 elastic tissue Anatomy 0.000 description 1
- 229920002549 elastin Polymers 0.000 description 1
- 239000002158 endotoxin Substances 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 230000007717 exclusion Effects 0.000 description 1
- 210000000416 exudates and transudate Anatomy 0.000 description 1
- 230000004438 eyesight Effects 0.000 description 1
- 239000000835 fiber Substances 0.000 description 1
- 238000007710 freezing Methods 0.000 description 1
- 230000008014 freezing Effects 0.000 description 1
- 238000001415 gene therapy Methods 0.000 description 1
- PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 description 1
- 239000010931 gold Substances 0.000 description 1
- 229910052737 gold Inorganic materials 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 230000005847 immunogenicity Effects 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 238000010832 independent-sample T-test Methods 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 230000002452 interceptive effect Effects 0.000 description 1
- 229910052742 iron Inorganic materials 0.000 description 1
- 206010023365 keratopathy Diseases 0.000 description 1
- 239000012160 loading buffer Substances 0.000 description 1
- 239000006166 lysate Substances 0.000 description 1
- 239000003550 marker Substances 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 230000010534 mechanism of action Effects 0.000 description 1
- 210000001724 microfibril Anatomy 0.000 description 1
- 238000000465 moulding Methods 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 230000003387 muscular Effects 0.000 description 1
- 230000002911 mydriatic effect Effects 0.000 description 1
- 230000003534 oscillatory effect Effects 0.000 description 1
- CMHHMUWAYWTMGS-UHFFFAOYSA-N oxybuprocaine Chemical compound CCCCOC1=CC(C(=O)OCCN(CC)CC)=CC=C1N CMHHMUWAYWTMGS-UHFFFAOYSA-N 0.000 description 1
- 229960003502 oxybuprocaine Drugs 0.000 description 1
- PRGUDWLMFLCODA-UHFFFAOYSA-N oxybuprocaine hydrochloride Chemical compound [Cl-].CCCCOC1=CC(C(=O)OCC[NH+](CC)CC)=CC=C1N PRGUDWLMFLCODA-UHFFFAOYSA-N 0.000 description 1
- 238000004806 packaging method and process Methods 0.000 description 1
- 238000012856 packing Methods 0.000 description 1
- 230000004796 pathophysiological change Effects 0.000 description 1
- 229960001412 pentobarbital Drugs 0.000 description 1
- 230000035699 permeability Effects 0.000 description 1
- 239000013612 plasmid Substances 0.000 description 1
- 229920000136 polysorbate Polymers 0.000 description 1
- 238000012257 pre-denaturation Methods 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 238000010298 pulverizing process Methods 0.000 description 1
- 239000011541 reaction mixture Substances 0.000 description 1
- 238000003753 real-time PCR Methods 0.000 description 1
- 238000007634 remodeling Methods 0.000 description 1
- 230000029058 respiratory gaseous exchange Effects 0.000 description 1
- 238000010839 reverse transcription Methods 0.000 description 1
- 229940043230 sarcosine Drugs 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 1
- 238000005063 solubilization Methods 0.000 description 1
- 230000010473 stable expression Effects 0.000 description 1
- 238000010186 staining Methods 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 239000012089 stop solution Substances 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 230000002194 synthesizing effect Effects 0.000 description 1
- 239000008399 tap water Substances 0.000 description 1
- 235000020679 tap water Nutrition 0.000 description 1
- 238000002626 targeted therapy Methods 0.000 description 1
- 238000010257 thawing Methods 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 238000003325 tomography Methods 0.000 description 1
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 1
- 238000002604 ultrasonography Methods 0.000 description 1
- 241000701161 unidentified adenovirus Species 0.000 description 1
- 210000001364 upper extremity Anatomy 0.000 description 1
- 238000011144 upstream manufacturing Methods 0.000 description 1
- 239000013603 viral vector Substances 0.000 description 1
- 230000000007 visual effect Effects 0.000 description 1
- 238000012800 visualization Methods 0.000 description 1
- 238000001262 western blot Methods 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/39—Connective tissue peptides, e.g. collagen, elastin, laminin, fibronectin, vitronectin, cold insoluble globulin [CIG]
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K67/00—Rearing or breeding animals, not otherwise provided for; New or modified breeds of animals
- A01K67/027—New or modified breeds of vertebrates
- A01K67/0275—Genetically modified vertebrates, e.g. transgenic
- A01K67/0276—Knock-out vertebrates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0048—Eye, e.g. artificial tears
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/10—Ophthalmic agents for accommodation disorders, e.g. myopia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2227/00—Animals characterised by species
- A01K2227/10—Mammal
- A01K2227/105—Murine
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2267/00—Animals characterised by purpose
- A01K2267/03—Animal model, e.g. for test or diseases
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
- C12N2750/00011—Details
- C12N2750/14011—Parvoviridae
- C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
- C12N2750/14141—Use of virus, viral particle or viral elements as a vector
- C12N2750/14143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Public Health (AREA)
- Genetics & Genomics (AREA)
- Zoology (AREA)
- Biomedical Technology (AREA)
- Epidemiology (AREA)
- Biotechnology (AREA)
- Ophthalmology & Optometry (AREA)
- Biophysics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Gastroenterology & Hepatology (AREA)
- Environmental Sciences (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biochemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Wood Science & Technology (AREA)
- General Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Dermatology (AREA)
- Physics & Mathematics (AREA)
- Plant Pathology (AREA)
- Microbiology (AREA)
- Virology (AREA)
- Animal Husbandry (AREA)
- Biodiversity & Conservation Biology (AREA)
- Toxicology (AREA)
- Immunology (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
本发明公开了原纤维蛋白‑2重组蛋白在制备预防或治疗原纤维蛋白‑2缺陷型眼病的产品中的用途。本发明首次通过用玻璃体腔注射FBN2基因干扰载体AAV构建FBN2基因缺陷型眼病小鼠模型的方法,且首次发现玻璃体腔注射FBN2重组蛋白对FBN2基因缺陷型眼病有治疗作用。本发明研究进一步证明了FBN2基因缺陷在眼组织视网膜病变和近视发展中一系列病理生理改变,以及玻璃体腔注射外源性FBN2重组蛋白可以弥补FBN2基因缺陷型眼病模型FBN2内源性缺失的问题,从而达到治疗疾病的作用,为一步靶向基因干预研究提供了新方法,并指明研究方向。
Description
技术领域
本发明涉及生物制药领域,具体涉及原纤维蛋白-2重组蛋白在制备预防或治疗原纤维蛋白-2缺陷型眼病的产品中的用途。
背景技术
原纤维蛋白-2(Fibrillin-2,FBN2)基因变异已经被证明是早发型黄斑变性(Early-onset macular degeneration,EOMD)、年龄相关性黄斑变性(Age relatedmacular degeneration,AMD)形成的重要原因,2014年在AMD家系中发现了 FBN2基因突变为常染色体显性遗传,2016年发现FBN2基因突变的AMD患者有玻璃膜疣的临床表现;有越来越多的人患有AMD,严重情况下会丧失视力。FBN2蛋白参与形成微纤维并对ECM的形成和重塑至关重要,参与全身结缔组织中弹性纤维的形成。FBN2基因变异的AMD患者眼中的FBN2蛋白表达降低或者功能丧失,这改变了其渗透性、弹性蛋白纤维的包装、以及柔韧性,这是诱发了视网膜病变的重要原因,但是FBN2基因缺陷在视网膜病变疾病中发生发展的作用机制尚不明确。
腺相关病毒(Adeno-associated virus,AAV)具有宿主范围广、有多种血清型、滴度高、安全性高、准确性高、表达稳定、免疫原性低等优点,已被广泛地应用于基础医学研究和临床试验中,被视为最有前途的研究基因治疗载体之一。
蛋白靶向干预广泛用于眼科疾病的治疗,如抗体(vascular endothelial growthfactor,VEGF)等,但是针对FBN2基因缺陷型视网膜病变和近视的靶向药物研究上尚未见报道。所以,本申请为FBN2基因缺陷型眼病的临床诊断和治疗提供新策略。
发明内容
针对现有技术中存在的缺陷,本发明的主要目的在于提供原纤维蛋白-2重组蛋白在制备预防或治疗原纤维蛋白-2缺陷型眼病的产品中的用途。
本申请通过AAV为载体进行RNAi构建的基因缺陷型眼病,通过注射重组蛋白进行靶向干预治疗,为视网膜病变的靶向治疗提供新的方法。本申请研究发现,通过AAV为载体进行RNAi可以构建的基因缺陷型视网膜疾病模型,主要表现为眼底出现玻璃膜疣样渗出物,视网膜相干光学断层扫描出现不光滑反射区,视网膜外颗粒层变薄,这些均为视网膜病变的临床表现。经过注射重组蛋白进行靶向干预治疗后,眼底渗出减少,视网膜外颗粒层增厚,对视网膜病变起到了一定的治疗作用。
一方面,本发明提供了一种原纤维蛋白-2重组蛋白在制备预防或治疗原纤维蛋白-2缺陷型眼病的产品中的用途。
进一步的,所述原纤维蛋白-2缺陷型眼病选自遗传性视网膜病变、轴性近视和先天性黄斑变性中的至少一种。
进一步的,所述产品为药物、试剂或疫苗。
在一个实施方式中,本发明提供了原纤维蛋白-2重组蛋白在非治疗目的调控视网膜电图波形振幅的用途;
优选的,所述调控视网膜电图波形振幅为将视网膜电图波形振幅恢复至正常;
优选的,所述视网膜电图波形振幅选自暗适应视杆细胞反应波形振幅、暗适应最大混合反应波形振幅、暗适应震荡电位反应波形振幅和明适应视锥细胞反应波形振幅中至少一种。
在一个实施方式中,本发明提供了原纤维蛋白-2重组蛋白在非治疗目的减少视网膜渗出及眼底沉积物的用途。
在一个实施方式中,本发明提供了原纤维蛋白-2重组蛋白在非治疗目的增加视网膜外核层厚度的用途。
在一个实施方式中,原纤维蛋白-2重组蛋白在非治疗目的降低眼轴长度的用途。
本发明提供了原纤维蛋白-2重组蛋白在非治疗目的提高原纤维蛋白-2的表达的用途;
优选的,所述原纤维蛋白-2的表达选自原纤维蛋白-2基因的表达或原纤维蛋白-2蛋白的表达;
优选的,所述原纤维蛋白-2基因的表达为原纤维蛋白-2基因mRNA的表达。
另一方面,本发明提供了一种预防或治疗原纤维蛋白-2缺陷型眼病的产品,所述产品是以原纤维蛋白-2重组蛋白作为唯一活性成分,或包含原纤维蛋白-2重组蛋白的组合物。
进一步,所述产品为药物,所述组合物还包括药用辅料;
优选的,所述药用辅料选自稀释剂、赋形剂、香味剂和甜味剂中的至少一种;
优选的,所述药物的制剂是混悬剂、乳剂、溶液剂、糖浆剂或注射剂中的至少一种;
优选的,所述药物的给药方式为滴注或注射;
优选的,所述药物的给药方式为玻璃体腔注射。
进一步,所述产品中原纤维蛋白-2重组蛋白的含量为0.01~5.0μg/μL;优选的,所述产品中原纤维蛋白-2重组蛋白的含量为0.1~1.0μg/μL;优选的,所述产品中原纤维蛋白-2重组蛋白的含量为0.2~0.5μg/μL。
本发明的有益效果如下:
1、本发明在FBN2基因缺陷型眼病模型构建以及注射FBN2蛋白的实验中证明,外源性FBN2重组蛋白可以改善FBN2基因缺陷引起的视网膜病变和近视性眼轴增长。
2、本发明通过注射FBN2基因干扰载体AAV后,可以构建FBN2基因缺陷型眼病小鼠模型,主要表现为眼底黄白色似玻璃膜疣沉积物、ONL变薄、眼轴增长、ERG波形振幅降低呈熄灭型,以及FBN2的mRNA和蛋白表达降低。
3、本发明通过注射外源性FBN2重组蛋白可以有效治疗FBN2基因缺陷型视网膜病变,可以减少眼底黄白色似玻璃膜疣沉积物的产生、增加ONL厚度、恢复ERG波形振幅、以及增加FBN2的mRNA和蛋白表达。
4、本发明首次通过用玻璃体腔注射FBN2基因干扰载体AAV构建FBN2 基因缺陷型动物模型的方法,且首次发现玻璃体腔注射FBN2重组蛋白对FBN2 基因缺陷型眼病有治疗作用。本发明研究进一步证明了FBN2基因缺陷在视网膜病变和近视发生发展中一系列病理生理改变,以及玻璃体腔注射外源性 FBN2重组蛋白可以弥补FBN2基因缺陷型眼病FBN2内源性缺失的问题,从而达到治疗疾病的作用,为下一步靶向基因干预研究提供了新方法,并指明研究方向。
附图说明
图1为经过不同处理后的扫描共聚焦检眼镜检查和光学相干断层扫描检测结果;
图2为经过不同处理后的Rod-b、Max-a、OPs total、Cone-b波形振幅的结果;
图3为经过不同处理后的眼轴长度的结果;a:视眼轴长度图;b:眼轴长度统计图;
图4为经过不同处理后的视网膜中FBN2基因的mRNA表达的结果;
图5为经过不同处理后的视网膜中FBN2蛋白表达的ELISA检测结果;
图6为经过不同处理后的视网膜中FBN2蛋白表达的western blot检测结果;
上述图中,*表示相同条件下的与正常对照组相比,在α=0.05水平下差异显著;&表示相同条件下的与阴性对照组相比,在α=0.05水平下差异显著;#表示相同条件下的与AAV组相比,在α=0.05水平下差异显著。
具体实施方式
下述实施例中所使用的实验方法如无特殊说明,均为常规方法。
下述实施例中使用的材料、试剂等,如无特殊说明,均可从商业途径得到。下述实施例中使用的FBN-2重组蛋白的纯度>97%。
实施例1
试验中使用8周龄C57BL/6J小鼠,SPF级,体质21-23g,入组前对小鼠进行眼部健康进行筛查,排除角膜病、白内障以及通过扫描激光检眼镜 (Scanning laserophthalmoscope,SLO)、光学相干断层扫描(Optical coherence tomography,OCT)和视网膜电图(Electroretinogram,ERG)分别排除视网膜眼底疾病。
构建FBN2腺病毒相关干扰载体:首先合成单链DNA低聚核苷酸,然后产生双链DNA低聚核苷酸,再通过其两端所含酶切位点(BamHI识别序列: 5'G^GATCC 3',EcoRI识别序列:5'G^AATTC 3')将其直接接上酶切后的 RNA干扰载体上;比对正确的克隆即为构建成功。共转染AAV-293细胞,包装病毒,收集原液,浓缩并纯化后得到浓缩液。抽提高纯度、无内毒素的AAV 载体,使用HG transgene reagent将构建好的病毒载体及质粒共转染进AAV-293 细胞,转染10~12h后加Enhancing buffer,接着8h后更换新鲜培养基,接着培养基48h后,细胞脱落后收集包括病毒的细胞及上清,之后对其浓缩、纯化后得到滴度为1.21E+12VG/mL的AAV病毒。
FBN-2重组蛋白的氨基酸序列为:
TPGRYECNCPPDFQLNPTGVGCVDNRVGNCYLKFGPRGDGSLSCNTEIGVG VSRSSCCCSLGKAWGNPCETCPPVNSTEYYTLCPGGEGFRPNPITIILEDIDEC QELPGLCQGGNCINTFGSFQCECPQGYYLSEDTRICEDIDECFAHPGVCGPG TCYNTLGNYTCICPPEYMQVNGGHNCMDMRKSFCYRSYNGTTCENELPFN VTKRMCCCTYNVGKAWNKPCEPCPTPGTADFKTIC。
FBN-2重组蛋白为大肠杆菌的宿主-载体系统有效地生成,稀释FBN-2重组蛋白的缓冲液包括20mM的Tris,150mM的NaCL,1mM的EDTA,1mM的二硫苏糖醇DTT,0.01%的十二烷基肌氨酸钠,5%的海藻糖和proclin300。FBN-2 重组蛋白的原始浓度为200μg/μL。
选取63只8周龄C57BL/6J小鼠,随机分为7组:正常对照组、阴性对照组、AAV组、FBN2超低浓度组(0.3μg/眼)、FBN2低浓度组(0.75μg/眼)、 FBN2中浓度组(1.5μg/眼)、FBN2高浓度组(3.0μg/眼)(n=9只/组)。正常对照组正常饲养不做任何处理;入组后,正常组正常饲养,阴性对照组双眼玻璃体腔注射3μL阴性病毒原液(AAV灭活病毒原液);AAV组、FBN2超低浓度组、FBN2低浓度组、FBN2中浓度组、FBN2高浓度组均双眼玻璃体腔注射 3μL AAV病毒进行FBN2基因缺陷型眼病造模。2周后,FBN2超低浓度组、 FBN2低浓度组、FBN2中浓度组、FBN2高浓度组分别双眼玻璃体腔注射浓度为0.1μg/μL、0.25μg/μL、0.50μg/μL、1μg/μL,剂量为3μL的FBN2重组蛋白, FBN2超低浓度组、FBN2低浓度组、FBN2中浓度组、FBN2高浓度组分别注射的FBN2重组蛋白量为0.3μg/眼、0.75μg/眼、1.5μg/眼、3μg/眼,每周注射 1次,连续注射3次。其中,玻璃体腔注射的具体操作包括:提前一天用氧氟沙星滴眼液(3次/d)对阴性对照组、AAV组、FBN2注射组动物进行眼部消炎。腹腔注射10g·L-1戊巴比妥钠溶液(50mg·kg-1)进行麻醉,保证正常呼吸,并滴散瞳药进行扩瞳。将麻醉的小鼠置于显微镜下,用聚维酮碘进行眼部周围消毒,1min后用0.9%生理盐水冲洗掉表面聚维酮碘,后用干燥无菌棉棒蘸干,用盐酸奥布卡因滴眼液进行眼表麻醉。用显微镜齿镊夹住球结膜,用微量注射器(10L),在角巩膜缘后进针,夹住针孔30s,松开镊子滴用典必殊滴眼液,术后1d继续滴用典必殊(3次)。
对实验结果数据的分析采用SPSS21.0统计软件,检验合正态分布,验方差齐性,涉及实验均为多组实验,均采用独立样本t检验的方差分析;计量资料用x±S表示,方差分析组间差异,Levene检验各组各指标方差齐性,P<0.05 认为差异具有统计学意义。
实施例2
FBN2重组蛋白每注射1次后,利用SLO检测眼底变化。
扫描共聚焦检眼镜检查SLO的具体操作包括:进行检测之前,先用腹腔注射10g·L-1戊巴比妥钠溶液(50mg·kg-1)进行麻醉,并扩瞳,并用氧氟沙星眼膏涂抹至角膜,待小鼠处于完全麻醉状态。将小鼠眼睛对准扫描激光眼底镜镜头,调整小鼠位置,以电脑显示屏可以拍到完整的眼地图为标准,每组取至少3张图片并保存图像,所有操作均由同一研究者进行,检测结果如图1所示。
由图1的结果可知,注射阴性病毒后,阴性对照组,与正常对照相比,视网膜眼底图无明显变化;注射AAV病毒后,AAV组和各FBN2注射组出现视网膜渗出,黄白色似玻璃膜疣沉积物。注射1次FBN2蛋白后,FBN2超低浓度组、FBN2低浓度组、FBN2中浓度组、FBN2高浓度组渗出及沉积物均无明显改变。注射2次FBN2蛋白后,FBN2低浓度组视网膜渗出及沉积物减少较明显,FBN2超低浓度组和中浓度组渗出及沉积物稍减少,FBN2高浓度组无明显改变。注射3次FBN2蛋白后,FBN2低浓度组视网膜渗出及沉积物明显减少,FBN2超低浓度组和中浓度组渗出及沉积物减少较明显,FBN2高浓度组渗出及沉积物稍减少变化不明显。
实施例3
FBN2重组蛋白每注射1次后,利用ERG分别检测检测视网膜功能。视网膜电图ERG的具体操作包括:ERG检测在绝对黑暗环境进行。检测前把小鼠置于黑暗环境8h以上,进行暗适应。进行检测之前,先用腹腔注射10g·L-1戊巴比妥钠溶液(50mg·kg-1)进行麻醉,并扩瞳,用盐酸奥布卡因滴眼液进行眼表麻醉,并用氧氟沙星眼膏涂抹至角膜,待小鼠处于完全麻醉状态。将动物置于操作台上,采用RETI port系统,将由金制的环状角膜电极(直径为3.00mm) 固定在小鼠双眼角膜,将针状参考电极分别插入小鼠口中左右口角两侧肌肉丰厚处,吧针状接地电极缓慢扎入小鼠右上肢皮下肌肉,待检测屏上地线稳定后,开始记录脑电图Rod-ERG、Max-ERG、Ops total、明适应10min后进行 Cone-ERG、Flick-ERG波形记录,以及各振幅变化,每个波形取3个数值,进行分析,结果如图2所示。
(1)暗适应视杆细胞反应(Rod-b)
入组时正常对照组、阴性对照组、AAV组、FBN2超低浓度组、FBN2 低浓度组、FBN2中浓度组、FBN2高浓度组Rod-b波值分别为(140.40±18.79 μV、138.41±17.42μV、141.35±15.80μV、140.22±18.33μV、140.97±17.58 μV、139.14±15.36μV、141.35±18.03μV)。
阴性AAV注射后,阴性对照组与正常对照相比,各时间点Rod-b波形振幅无明显变化(阴性AAV注射后:138.91±18.93μV对比139.78±16.66μV ;FBN2注射1次:142.91±17.44μV对比140.97±16.09μV,FBN2注射2次:141.16±15.09μV对比141.29±19.72μV;FBN2注射3次:136.91±17.73μV 对比145.38±18.31,P>0.05);AAV注射后,各组与阴性对照组相比Rod-b 波形振幅均变平缓,呈熄灭型(AAV组对比阴性对照组:27.18±4.21对比138.91±18.93μV;FBN2超低浓度组对比阴性对照组:28.32±3.78μV对比138.91±18.93μV;FBN2低浓度组对比阴性对照组:22.26±4.02μV对比 138.91±18.93μV,FBN2中浓度组对比阴性对照组:23.45±4.27μV对比 138.91±18.93μV,FBN2高浓度组对比阴性对照组:24.11±3.78μV对比 138.91±18.93μV,P<0.05)。
FBN2蛋白注射1次后,各组与AAV组相比Rod-b波形振幅无明显变化 (FBN2超低浓度组对比AAV组:26.44±3.67μV对比26.28±4.33μV;FBN2 低浓度组对比AAV组:32.95±5.67μV对比26.28±4.33μV;FBN2中浓度组对比AAV组:30.38±4.29μV对比26.28±4.33μV;FBN2高浓度组对比AAV 组:27.55±1.79μV对比26.28±4.33μV,P>0.05);各组与AAV组比较,Rod-b 波形振幅均变平缓,呈熄灭型(AAV组对比阴性对照组:26.28±4.33μV对比142.91±17.44μV;FBN2超低浓度组对比阴性对照组:26.44±3.67μV对比142.91±17.44μV;FBN2低浓度组对比阴性对照组:32.95±5.67μV对比142.91 ±17.44μV;FBN2中浓度组对比阴性对照组:30.38±4.29μV对比142.91± 17.44μV;FBN2高浓度组对比阴性对照组:27.55±1.79μV对比142.91±17.44 μV,P<0.05);各组与正常对照组比较趋势和与阴性对照组比较趋势一致。
FBN2蛋白注射2次后,FBN2低浓度组与AAV组相比,波形振幅增大(76.33 ±7.46μV对比25.96±4.59μV,P<0.05);FBN2超低浓度组、FBN2中浓度组、 FBN2高浓度组与AAV组相比Rod-b波形振幅无明显变化,(FBN2超低浓度组对比AAV组:28.97±5.00μV对比25.96±4.59μV;FBN2中浓度组对比AAV 组:39.79±6.17μV对比25.96±4.59μV;FBN2高浓度组对比AAV组:30.40 ±4.42μV对比25.96±4.59μV,P>0.05)。各组与阴性对照组相比,Rod-b波形振幅均明显较低,(AAV组对比阴性对照组:25.96±4.59μV对比141.16± 15.09μV;FBN2超低浓度组对比阴性对照组:28.97±5.00μV对比141.16± 15.09μV;FBN2低浓度组对比阴性对照组:76.33±7.46μV对比141.16±15.09 μV;FBN2中浓度组对比阴性对照组:39.79±6.17μV对比141.16±15.09μV; FBN2高浓度组对比阴性对照组:30.40±4.42μV对比141.16±15.09μV,P< 0.05);各组与正常对照组比较趋势和与阴性对照组比较趋势一致。
FBN2蛋白注射3次后,FBN2低浓度组、FBN2中浓度组与AAV组相比, Rod-b波形振幅明显增大(FBN2低浓度组对比AAV组:118.33±12.42μV对比26.25±3.88μV;FBN2中浓度组对比AAV组:77.00±8.51μV对比26.25±3.88 μV,P<0.05),FBN2超低浓度组、FBN2高浓度组与AAV组相比Rod-b波形振幅无明显变化(FBN2超低浓度组对比AAV组:31.25±4.79μV对比26.25±3.88 μV;FBN2高浓度组对比AAV组:58.88±5.32μV对比26.25±3.88μV,P>0.05)。与阴性对照组相比,FBN2低浓度组Rod-b波形振幅差异无明显变化, (118.33±12.42对比136.91±17.73μV,P>0.05),AAV组、FBN2超低浓度组、FBN2中浓度组、FBN2高浓度组Rod-b波形振幅均明显较低(AAV组对比阴性对照组:26.25±3.88μV对比136.91±17.73μV;FBN2超低浓度组对比阴性对照组:31.25±4.79μV对比136.91±17.73μV;FBN2中浓度组对比阴性对照组:77.00±8.51μV对比136.91±17.73μV;FBN2高浓度组对比阴性对照组: 58.88±5.32μV对比136.91±17.73μV,P>0.05);各组与正常对照组比较趋势和与阴性对照组比较趋势一致。
(2)暗适应最大混合反应(Max-a)
入组时正常对照组、阴性对照组、AAV组、FBN2超低浓度组、FBN2低浓度组、FBN2中浓度组、FBN2高浓度组Rod-b波值分别为(-121.97±18.67μV、 -123.85±16.48μV、-117.26±17.83μV、-119.77±18.63μV、-115.7±17.88μV、 -121.97±15.46μV、-117.26±15.33μV)。
阴性AAV注射后,阴性对照组与正常对照组相比,实验各时间点Max-a波无明显变化(阴性AAV注射后:-116.07±18.77μV对比-116.45±17.44μV;FBN2 注射1次:-117.05±15.83μV对比-117.45±17.33μV;FBN2注射2次:-118.29 ±17.42μV对比-116.45±18.68μV;FBN2注射3次:-116.05±16.71μV对比 -119.5±17.33μV,P>0.05);AAV注射后,各组与阴性对照组,Max-a波形振幅均变平缓,呈熄灭型(AAV组对比阴性对照组:-18.90±2.84μV对比-116.07± 18.77μV;FBN2超低浓度组对比阴性对照组:-17.19±2.67μV对比-116.07± 18.77μV;FBN2低浓度组对比阴性对照组:-15.65±2.35μV对比-116.07±18.77 μV;FBN2中浓度组对比阴性对照组:-17.90±2.79μV对比-116.07±18.77μV; FBN2高浓度组对比阴性对照组:-15.07±3.07μV对比-116.07±18.77μV,P< 0.05);各组与正常对照组比较趋势同与阴性对照组比较趋势一致。
FBN2蛋白注射1次后,各组与AAV组相比,FBN2超低浓度组、FBN2低浓度组、FBN2中浓度组、FBN2高浓度组视网膜电图波形振幅无明显变化,(FBN2 超低浓度组对比AAV组:-19.49±2.33μV对比-18.40±3.33μV;FBN2低浓度组对比AAV组:-25.65±5.22μV对比-18.40±3.33μV;FBN2中浓度组对比AAV 组:-22.53±4.67μV对比-18.40±3.33μV;FBN2高浓度组对比AAV组:-19.90 ±3.67μV对比-18.40±3.33μV,P>0.05);各组与阴性对照组比较,MAX-a波形振幅均变平缓,呈熄灭型,(AAV组对比阴性对照组:-18.40±3.33μV对比 -117.05±15.83μV;FBN2超低浓度组对比阴性对照组:-19.49±2.33μV对比 -117.05±15.83μV;FBN2低浓度组对比阴性对照组:-25.65±5.22μV对比 -117.05±15.83μV;FBN2中浓度组对比阴性对照组:-22.53±4.67μV对比 -117.05±15.83μV;FBN2高浓度组对比阴性对照组:-19.90±3.67μV对比 -117.05±15.83,P<0.05);各组与正常对照组比较趋势同与阴性对照组比较趋势一致。
FBN2蛋白注射2次后,FBN2低浓度组、FBN2中浓度组与AAV组相比, Max-a波形振幅略增大(FBN2低浓度组对比AAV组:-67.95±5.67μV对比-19.82 ±3.85μV;FBN2中浓度组对比AAV组:-27.24±6.67μV对比-19.82±3.85μV, P<0.05),FBN2超低浓度组、FBN2高浓度组与AAV组相比Max-a波形振幅无明显变化(BN2超低浓度组与AAV组相比:-23.94±6.67μV对比-19.82±3.85μV; FBN2高浓度组与AAV组相比:-24.54±5.44μV对比-19.82±3.85μV,P>0.05);各组与阴性对照组相比,AAV组、FBN2超低浓度组、FBN2低浓度组、FBN2中浓度组、FBN2高浓度组Max-a波形振幅低平,(AAV组对比阴性对照组:-19.82 ±3.85μV对比-118.29±17.42μV;FBN2超低浓度组对比阴性对照组:-23.94 ±6.67μV对比-118.29±17.42μV;FBN2低浓度组对比阴性对照组:-67.95± 5.67μV对比-118.29±17.42μV;FBN2中浓度组对比阴性对照组:-27.24±6.67 μV对比-118.29±17.42μV;FBN2高浓度组对比阴性对照组:-24.54±5.44μV对比-118.29±17.42μV,P<0.05);各组与正常对照组比较趋势同与阴性对照组比较趋势一致。
FBN2蛋白注射3次后,FBN2低浓度组、FBN2中浓度组与AAV组相比, Max-a波形振幅均增大(FBN2低浓度组对比AAV组:-99.44±9.42对比-19.17 ±3.67μV,FBN2中浓度组对比AAV组-65.27±8.67μV对比-19.17±3.67μV, P<0.05);FBN2超低浓度组、FBN2高浓度组与AAV组相比Max-a波形振幅无明显变化(FBN2超低浓度组与AAV组:-24.72±4.33μV对比-19.17±3.67 μV;FBN2高浓度组与AAV组:-30.57±5.88μV对比-19.17±3.67μV,P>0.05)。FBN2低浓度组、FBN2中浓度组与阴性对照组相比,Max-a波形振幅无明显差异,(FBN2低浓度组对比阴性对照组:-99.44±9.42μV对比-116.05±16.71μV; FBN2中浓度组对比阴性对照组:-65.27±8.67μV对比-116.05±16.71μV;P> 0.05),AAV组、FBN2超低浓度组、FBN2高浓度组较阴性对照组Max-a波形振幅明显低平(AAV组对比阴性对照组:-19.17±3.67μV对比-116.05±16.71 μV;FBN2超低浓度组对比阴性对照组:-24.72±4.33μV对比-116.05±16.71 μV;FBN2高浓度组对比阴性对照组:-30.57±5.88μV对比-116.05±16.71μV,);各组与正常对照组比较趋势同与阴性对照组比较趋势一致。
(3)暗适应震荡电位反应(OPs total)
入组时正常对照组、阴性对照组、AAV组、FBN2超低浓度组、FBN2低浓度组、FBN2中浓度组、FBN2高浓度组OPs-total波值分别为(234.95±19.33μV、 226.28±20.21μV、230.61±19.47μV、231.45±20.22μV、232.11±18.67μV、226.58 ±21.03μV、233.62±19.45μV)。
阴性AAV注射后,阴性对照组与正常对照组相比,实验各时间点OPs-total 波无明显变化(阴性AAV注射后:229.28±19.67μV对比238.56±20.44μV; FBN2注射1次:226.7±18.37μV对比250.95±21.33μV;FBN2注射2次:229.28 ±21.33μV对比222.95±18.67μV;FBN2注射3次:272.8±21.34μV对比 234.95±22.67μV,P>0.05)。AAV注射后,各组与阴性对照组相比OPs-total 波形振幅均变平缓,呈熄灭型,(AAV组对比阴性对照组:19.56±2.97μV对比 229.28±19.67μV;FBN2超低浓度组对比阴性对照组:19.96±3.03μV对比229.28±19.67μV;FBN2低浓度组对比阴性对照组:22.75±3.57μV对比229.28 ±19.67μV;FBN2中浓度组对比阴性对照组:21.56±4.05μV对比229.28± 19.67μV;FBN2高浓度组对比阴性对照组:26.75±3.33μV对比229.28±19.67 μV,P<0.05);各组与正常对照组比较趋势同与阴性对照组比较趋势一致。
FBN2蛋白注射1次后,各蛋白注射组与AAV组相比,FBN2超低浓度组、FBN2低浓度组、FBN2中浓度组、FBN2高浓度组OPs-total波形振幅无明显变化,(FBN2超低浓度组对比AAV组:25.48±3.44μV对比22.23±3.90μV; FBN2低浓度组对比AAV组:29.73±4.03μV对比22.23±3.90μV;FBN2中浓度组对比AAV组:26.37±3.67μV对比22.23±3.90μV;FBN2高浓度组对比 AAV组:25.39±4.85μV对比22.23±3.90μV,P>0.05)。各组与阴性对照组相比,OPs-total波形振幅均平缓,呈熄灭型(AAV组对比阴性对照组:22.23±3.90 μV对比226.7±18.37μV;FBN2超低浓度组对比阴性对照组:25.48±3.44μV 对比226.7±18.37μV;FBN2低浓度组对比阴性对照组:29.73±4.03μV对比 226.7±18.37μV;FBN2中浓度组对比阴性对照组:26.37±3.67μV对比226.7 ±18.37μV;FBN2高浓度组对比阴性对照组:25.39±4.85μV对比226.7± 18.37μV,P<0.05);各组与正常对照组比较趋势同与阴性对照组比较趋势一致。
FBN2蛋白注射2次后,FBN2低浓度组与AAV组相比,OPs-total波形振幅变大,(107.03±18.03μV对比24.51±8.67μV,P<0.05),FBN2超低中浓度组、FBN2中浓度组、FBN2高浓度组OPs-total波形振幅无明显变化(FBN2超低浓度组对比AAV组35.03±9.55μV对比24.51±8.67μV;FBN2中浓度组对比AAV组44.91±14.53μV对比24.51±8.67μV,FBN2高浓度组对比AAV组 30.18±5.44μV对比24.51±8.67μV,P>0.05)。各组与阴性对照组相比,OPs-total波形振幅均明显变平缓,(AAV组对比阴性对照组:24.51±8.67μV对比229.28±21.33μV;FBN2超低浓度组对比阴性对照组:35.03±9.55μV对比 229.28±21.33μV;FBN2低浓度组对比阴性对照组:107.03±18.03μV对比 229.28±21.33μV;FBN2中浓度组对比阴性对照组:44.91±14.53μV对比 229.28±21.33μV;FBN2高浓度组对比阴性对照组:30.18±5.44μV对比229.28 ±21.33μV,P<0.05);各组与正常对照组比较趋势同与阴性对照组比较趋势一致。
FBN2蛋白注射3次后,FBN2低浓度组与AAV组相比,OPs total波形振幅明显增大,(133.56±18.77μV对比25.08±8.76μV,P<0.05);FBN2超低浓度组、FBN2中浓度组、FBN2高浓度组与AAV组相比OPs-total波形振幅均无明显变化(FBN2超低浓度组对比AAV组:37.83±6.97μV对比25.08±8.76 μV;FBN2中浓度组对比AAV组:70.75±23.33μV对比25.08±8.76μV;FBN2 高浓度组对比AAV组:58.31±9.24μV对比25.08±8.76μV,P>0.05)。FBN2 低浓度组与阴性对照组相比,OPs total波形振幅无变化(133.56±18.77μV对比272.8±21.34μV,P>0.05);AAV组、FBN2超低浓度组、FBN2中浓度组、 FBN2高浓度组与阴性对照组相比,OPs-total波形振幅均明显平缓,(AAV组对比阴性对照组:25.08±8.76μV对比272.8±21.34μV;FBN2超低浓度组对比阴性对照组:37.83±6.97μV对比272.8±21.34μV;FBN2中浓度组对比阴性对照组:70.75±23.33μV对比272.8±21.34μV;FBN2高浓度组对比阴性对照组:58.31±9.24μV对比272.8±21.34μV,P<0.05);各组与正常对照组比较趋势同与阴性对照组比较趋势一致。
(4)明适应视锥细胞反应(Cone-b)
入组时正常对照组、阴性对照组、AAV组、FBN2超低浓度组、FBN2低浓度组、FBN2中浓度组、FBN2高浓度组Cone-b波波值分别为(72.33±8.03μV 、72.61±9.64μV、69.88±9.59μV、72.46±10.33μV、74.53±10.67μV、72.61 ±11.44μV、69.88±9.82μV)。
阴性AAV注射后,阴性对照组与正常对照组相比,实验各时间点OPs-total 波无明显变化(阴性AAV注射后:69.56±11.33μV对比71.21±10.17μV;FBN2 注射1次:68.77±9.33μV对比75.21±9.47μV;FBN2注射2次:70.23±6.63μV 对比77.22±8.93μV;FBN2注射3次:71.03±8.44μV对比77.31±9.03μV,P >0.05)。AAV注射后,各组与阴性对照组相比,Cone-b波形振幅均变平缓,呈熄灭型,(AAV组对比阴性对照组:3.89±2.82μV对比69.56±11.33μV,FBN2 超低浓度组对比阴性对照组:4.77±2.63μV对比69.56±11.33μV,FBN2低浓度组对比阴性对照组:3.43±3.44μV对比69.56±11.33μV,FBN2中浓度组对比阴性对照组:3.68±2.51μV对比69.56±11.33μV,FBN2高浓度组对比阴性对照组:3.47±1.67μV对比69.56±11.33μV,P<0.05);各组与正常对照组比较趋势同与阴性对照组比较趋势一致。
FBN2蛋白注射1次后,各蛋白注射组与AAV组相比,Cone-b波形振幅无明显变化,(FBN2超低低浓度组对比AAV组:3.93±2.56μV对比3.03±2.02μV, FBN2低浓度组对比AAV组:6.21±2.67μV对比3.03±2.02μV,FBN2中浓度组对比AAV组:4.44±3.33μV对比3.03±2.02μV,FBN2高浓度组对比AAV 组:3.99±1.95μV对比3.03±2.02μV,P>0.05)。各组与阴性对照组比Cone-b 波形振幅均变平缓,呈熄灭型,(AAV组对比阴性对照组:3.03±2.02μV对比 68.77±9.33μV,FBN2超低浓度组对比阴性对照组:3.93±2.56μV对比68.77 ±9.33μV,FBN2低浓度组对比阴性对照组:6.21±2.67μV对比68.77±9.33 μV,FBN2中浓度组对比阴性对照组:4.44±3.33μV对比68.77±9.33μV, FBN2高浓度组对比阴性对照组:3.99±1.95μV对比68.77±9.33μV,P< 0.05);各组与正常对照组比较趋势同与阴性对照组比较趋势一致。
FBN2蛋白注射2次后,各蛋白注射组与AAV组相比,Cone-b波形振幅无明显变化,(FBN2超低浓度组对比AAV组:7.67±3.22μV对比3.67±2.97 μV;FBN2低浓度组对比AAV组:21.18±8.48μV对比3.67±2.97μV;FBN2 中浓度组对比AAV组:10.86±4.03μV对比3.67±2.97μV;FBN2高浓度组对比AAV组:8.05±3.33μV对比3.67±2.97μV,P>0.05)。各组与阴性对照组相比,Cone-b波形振幅均明显平缓,(AAV组对比阴性对照组:3.67±2.97μV 对比70.23±6.63μV;FBN2超低浓度组对比阴性对照组:7.67±3.22μV对比 70.23±6.63μV;FBN2低浓度组对比阴性对照组:21.18±8.48μV对比70.23 ±6.63μV;FBN2中浓度组对比阴性对照组:10.86±4.03μV对比70.23±6.63 μV;FBN2高浓度组对比阴性对照组:8.05±3.33μV对比70.23±6.63μV,P <0.05);各组与正常对照组比较趋势同与阴性对照组比较趋势一致。
注射3次FBN2蛋白后,与AAV组相比,FBN2低浓度组Cone-b波形振幅明显增大,25.61±7.67μV对比3.17±2.11μV,P<0.05),FBN2超低浓度组、 FBN2中浓度组、FBN2高浓度组Cone-b波形振幅均无明显变化(FBN2超低浓度组对比AAV组:8.55±5.42μV对比3.17±2.11μV,FBN2中浓度组对比AAV 组:18.57±8.03μV对比3.17±2.11μV,FBN2高浓度组对比AAV组:10.66 ±4.43μV对比3.17±2.11μV,P>0.05)。各组与阴性对照组相比,Cone-b波形振幅均明显平缓,但FBN2超低浓度组的治疗效应最明显(AAV组对比阴性对照组:3.17±2.11μV对比71.03±8.44μV;FBN2超低浓度组对比阴性对照组:8.55±5.42μV对比71.03±8.44μV;FBN2低浓度组对比阴性对照组:25.61 ±7.67μV对比71.03±8.44μV;FBN2中浓度组对比阴性对照组:18.57±8.03 μV对比71.03±8.44μV;FBN2高浓度组对比阴性对照组:10.66±4.43μV对比71.03±8.44μV,,P<0.05);各组与正常对照组比较趋势同与阴性对照组。
实施例4
FBN2重组蛋白每注射1次后,利用OCT检测眼轴长度。
光学相干断层扫描OCT的具体操作包括:进行检测之前,先用腹腔注射 10gL-1戊巴比妥钠溶液(50mgkg-1)进行麻醉,并扩瞳,并用氧氟沙星眼膏涂抹至角膜,待小鼠处于完全麻醉状态。为小鼠配戴直径为3mm、屈光度为 -25D的角膜接触镜,将小鼠眼睛对准扫描镜头,调整小鼠位置、和镜头距离,以电脑显示屏可以拍到位置准确的断层图,为标准,每组取至少3张图片并保存图像,进行拍摄并图像分析,测量眼轴长度,结果如图3所示。sh性AAV/AAV 注射后,阴性对照组眼轴长度为(3.29±0.09mm),AAV组和FBN2蛋白注射组眼轴长度为(3.31±0.11mm,3.31±0.12mm),无统计学意义(P>0.05)。对重组蛋白组注射3次FBN2重组蛋白,每次间隔9天;同时对AAV组注射等量的Ringer's注射缓冲液。注射完成后,AAV组眼轴长度明显大于阴性对照组、正常对照组(AAV组对比阴性对照组:3.68±0.10mm对比3.40±0.03mm;AAV 组对比阴性对照组:3.68±0.10mm对比3.40±0.09mm,P<0.05);FBN2低浓度蛋白注射组眼轴显著低于AAV组(3.35±0.03mm对比3.68±0.10mm,P<0.05);FBN2低浓度蛋白注射组眼轴与阴性对照组、正常对照组比较无统计学意义(P>0.05)。
实施例5
实验时每组挑选6个视网膜组织。视网膜组织总RNA的提取和RT-PCR 的反应按照以下方法进行。
1、总RNA的提取
(1)组织研磨:将冻存的视网膜组织取出,液氮中转移,用玻璃棒研磨,加入200μlTrizol研磨2min,重复研磨,待EP管中无可见的视网膜组织后,在加入500μl Trizol吹打混匀(注:样本样本量不能超过Trizol试剂体积的 10%)。
(2)分离:静置5min,待核蛋白复合体彻底分离后,加入150μl氯仿(三氯甲烷),剧烈震荡数次,静置2-3min(15-30℃),后置于预冷的高速离心机中离心,4℃下转速20min,14500g,离心结束后,RNA存在于上层液体中;
(3)RNA沉淀:将上层透明液体转移至1.5mL EP管中,加入0.3mL 异丙醇,吹打混匀,室温静置,后置于预冷的高速离心机中离心,4℃下转速 20min,14500g;
(4)RNA洗涤:去上清,加入1ml由0.25mL和DEPC水0.75mL无水乙醇配制75%乙醇,后置于预冷的高速离心机中离心,4℃下转速20min, 14500g;
(5)RNA再溶解:去上清,后置于预冷的高速离心机中离心,4℃下转速20min,14500g,用枪轻吸除多余液体,干燥3min后,加入30μl DEPC水,以溶解RNA沉淀,吹打混匀;
(6)RNA样本的OD260/OD280的数值在1.8-2.0间为有意义,于K5600 超微量分光光度计测定RNA纯度和浓度取1μLRNA样品,进行分装,减少因反复冻融,之后进行反转录,将剩余的RNA样本分装保存在-80℃避免RNA 降解。
2、第一链cDNA合成
(1)依次加入1μL Random 6mers、2μL RNase Free dH2O、dNTP Mixture、 1μLOligo dT Primer和5μL RNA样本,混匀后离心;
(2)温育5min,65℃金属恒温锅;
(3)依次加入1μLPrimeScriptⅡRTase、0.5μLRNase Inhabitor、4μL 5×PrimeScriptⅡBuffer、4.5μL RNase Free dH2O,混匀后离心;
(4)温育10min(30℃),后转移至42℃水浴锅60min;
(5)放入95℃金属恒温锅中,使反转录酶失活(5min)。
3、设计与合成引物
引物序列合成与由上海生工,β-actin为内参,引物序列见表1。
表1视网膜各分子引物序列表
4、实时荧光定量PCR反应
采用II RT-PCR仪检测各组小鼠视网膜中FBN2、β-actin mRNA的相对表达量。FBN2基因设置3个复孔,使用96孔板,总体积为20μL,包括:稀释20倍后的8μLcDNA模板,上下游引物均为1μL,SYBR Green I Master加10μL,封膜,轻度离心。反应条件为:预变性95℃5min,变性95℃10s,54℃退火30s,72℃延伸30s,共45个循环,最后40℃冷却10s。采用2-△△CT方法,以β-actin为内参。通过2-△△CT方法计算FBN2抗体组和PBS组中相对于正常对照组的基因表达水平倍数的变化,对各组小鼠视网膜中FBN2、β-actin mRNA的相对表达量进行定量分析,结果如图4所示。
由图4的结果可知,阴性AAV注射后,阴性对照组[(3.08±0.39)×10-3] 与正常对照组[(3.16±0.45)×10-3]相比,FBN2基因的mRNA的表达均无明显变化(P>0.05)。AAV后注射,与阴性对照组[(3.16±0.45)×10-3]比, AAV组[(1.36±0.24)×10-3]、FBN2超低浓度组[(1.35±0.26)×10-3]、FBN2 低浓度组[(1.45±0.30)×10-3]、FBN2中浓度组[(1.54±0.41)×10-3]、FBN2 高浓度组[(1.55±0.04)×10-3],FBN2基因的mRNA表达均明显下降,(P<0.05)。
FBN2蛋白注射3次后,FBN2低浓度组[(3.00±0.37)×10-3]FBN2基因的 mRNA表达比AAV组[(1.48±0.60)×10-3]明显增加(P<0.05);FBN2超低浓度组[(1.69±0.71)×10-3]、FBN2中浓度组[(2.01±0.22)×10-3]、FBN2高浓度组[(1.51±0.37)×10-3]与AAV组[(1.48±0.60)×10-3]比较FBN2基因的 mRNA表达均无明显变化(P>0.05)。
FBN2低浓度组[(3.00±0.37)×10-3]FBN2基因的mRNA表达与阴性对照组[(3.22±0.30)×10-3]比较无明显变化(P>0.05);AAV组[(1.48±0.60)×10-3]、 FBN2超低浓度组[(1.69±0.71)×10-3]、FBN2中浓度组[(2.01±0.22)×10-3]、 FBN2高浓度组[(1.51±0.37)×10-3]与阴性对照组[(3.22±0.30)×10-3]比较 FBN2基因的mRNA表达均明显下降(P<0.05);各组与正常对照组比较趋势同与阴性对照组比较趋势一致。
实施例6
实验结束后,腹腔注射过量10g·L-1戊巴比妥钠溶液处死小鼠,用弯镊摘除眼球放入生理盐水中涮洗一下,放在蔡司显微镜下,沿角巩膜缘剪开后去用虹膜恢复器轻轻分离出视网膜存于无菌无酶1.5ml EP管,液氮速冻,-80℃保存备用。实验时每组挑选6个视网膜组织,液氮中转移。在组织中加入组织裂解液,置于于冰上,使用玻璃棒进行研磨,然后将粉碎后的匀浆,吸取上清,再用超声粉碎,然后将匀浆按上述离心条件离心,吸取上清利-80℃保存。用BCA法检测样品浓度,并按照说明书进行ELISA检测、分析FBN2蛋白的表达。具体步骤如下:
(1)试剂盒室温平衡,60min;
(2)在标准品孔,按要求各加的50μL标准品;
(3)样品孔,各50μL加检测样品,空白孔加稀释液50μL;
(4)各孔加100μL HRP标记得检测抗体,封孔,37℃恒温60min;
(5)配洗涤液:稀释至1×;
(6)弃去液体后拍干,每孔350μL洗涤液,1min后拍干,重复5次;
(7)每孔加入各50μL底物(A、B),37℃孵孵育15min(避光);
(8)加入终止液50μL每孔;
(9)在450nm波长下测定各孔的OD值;
(10)根据标准品浓度梯度和OD值计算标准曲线计算视网膜中目的蛋白相对含量,结果如图5所示。
由图5的结果可知,阴性AAV注射后,阴性对照组(7.11±0.98μg/ml)与正常对照组(7.13±1.13μg/ml)相比,蛋白的表达无明显差异(P>0.05)。AAV 后注射,AAV组(4.02±0.92μg/ml)、FBN2超低浓度组(4.21±0.96μg/ml)、 FBN2低浓度组(4.23±0.89μg/ml)、FBN2中浓度组(4.30±0.39μg/ml)、FBN2 高浓度组(4.00±0.70μg/ml)与阴性对照组(7.11±0.98μg/ml)比,蛋白表达均明显下降(P<0.05),各组与正常对照组比较趋势同与阴性对照组比较趋势一致。FBN2蛋白注射3次后,FBN2低浓度组(7.51±0.87μg/ml)蛋白表达比AAV组(4.21±0.79μg/ml)明显增加(P<0.05);FBN2超低浓度组(4.58±0.80 μg/ml)、FBN2中浓度组(6.12±0.77μg/ml)、FBN2高浓度组(5.01±0.36μg/ml) 与AAV组(4.21±0.79μg/ml)比较蛋白表达均无明显变化(P>0.05)。AAV 组(4.21±0.79μg/ml)、FBN2超低浓度组(4.58±0.80μg/ml)、FBN2中浓度组 (6.12±0.77μg/ml)、FBN2高浓度组(5.01±0.36μg/ml)与阴性对照组(7.70±0.94 μg/ml)比较蛋白表达均明显下降(P<0.05);各组与正常对照组比较趋势同与阴性对照组比较趋势一致。
实施例7
制备蛋白样品,将各组样品与SDS-PAGE蛋白上样缓冲液按体积比5:1充分混匀,每组取3个样品等比混合,随后100℃煮沸6min,待样品放冷至室温后,放于-80℃冰箱中备用。
1、配胶
(1)刷玻璃板:流洁精+水,蒸馏水冲洗,晾干/吹干;
(2)夹板固定,加入无水乙醇4-5ml测漏,5min后不满倒掉;
(3)配分离胶:①丙烯酰胺(30%);②10%APS:现配现用:0.1g过硫酸胺;③Tns-HCI-SDS:用前摇匀,SDS结晶析出;④APS TEMED:冰上操作;⑤配镁丙烯酰胺:APS TEMED放回4℃冰箱;
(4)灌注后,加元水乙醒压平液面,不可用水;
(5)静置45min(可长不可短);
(6)配5%积层胶,倒出乙醇、倾斜,滤纸吸干,加积层胶在玻璃板
顶部,按儒插入蓝梳子;
(7)静置45min,将梳子垂直向上,缓慢拔出,在中间部位依次加入Mark, 样品。将两块矮板对内,放入电泳槽中,两板之间加入适量电泳液,置于吸水纸上测,若不漏继续加,接近低矮板时停止。
2、电泳与转膜:
(1)将稀释的电泳液倒入电泳槽(两端对内向上),放纸上测漏;
(2)若不漏水,放入盒加满电泳液,小心拔出梳子,正常组组织注意;
(3)取出样品离心12000r/min,放在冰上,预染分子蛋白等;
(4)上样Marker 5ul,蛋白样品抽取上层,不儒抽到底部沉淀①上样时,加样器斜面抵住后玻璃板,缓慢加样。②换样前,蒸馏水多次冲洗加样器;
(5)电流槽加满,注意可用上样器,以免样品被冲出,槽外加液设过铁丝;
(6)80v 30mh后转为100v 120min;
(7)转膜前将1×转膜液提前20min放入-80℃冰箱预冷;
(8)剪滤纸PVDF膜,将转膜液倒入托盘中泡滤纸,PVD放入甲醇中泡 30m,后用三蒸水水冲干净;
(9)电泳结后,取出玻璃板,用切板将上层胶切掉,制下的胶取下放入托
盆中,注意正反与左右,回收电流液;
(10)黑板→单层海棉→三层滤纸→胶-PVDF膜,三层滤低-海绵-透明板一层一层辅;
(11)将板合好扣紧放入槽中,黑时黑,红对红,放入冰盆,加满转膜液;
(12)分清正负极后盖好,100v 120min,4℃冰盖好;200mA/100min;
(13)TBST:10×TBST+900ml水+500mlTween悬液摇2h;
(14)转膜后,左上角剪角后取下,角左右放置在封口袋中,倒入10ml 封闭液,摇床1h.封闭完善,TBST清洗3×5min之后抗体卵孵育检测;
(15)转膜液回收,清洗盆子,夹板海绵,海绵,先自来水泡后蒸馏泡,取出后置于托盘晾干3/4TBST稀释倍数→说明书.稀释液:1/4封闭液;
(16)封闭过程中配一抗,做口袋;
(17)口袋标记好,封闭液倒出后剪条带,按名称放入对应口袋,封口,加一抗①条带均作标记,②赶走气泡封口,③口袋作相应抗体;
(18)各条带固定后置于摇床上,0.5h-11(宜长不宜短),放入4℃过夜。
3、配二抗显影
(1)膜放入摇床45min.最长不超过2h;
(2)TBST:4x8ml洗;
(3)做二抗口袋:配二抗稀释液,1/4封闭液.3/4TBST;
(4)条带置于口袋中,加二抗,赶气泡,摇床1h;
(5)配AB液,回收二抗;
(6)TBST洗条带,4×8min;TBS洗2×5min(防止TST干扰显影);
(7)AB液滴在干净的板上,条带正面接触,反应2min,进行曝光。保存条带,将显影后的条带用TBST洗2遍,10min,20min时间非限定,再由TBST 洗一遍,然后TBS封存;检测结果如图6所示。
表2
FBN2蛋白注射组为治疗效果最好的FBN2低浓度组。由图6的结果可知,阴性AAV注射后,阴性对照组与正常对照组相比,视网膜的FBN2基因的蛋白的表达无明显变化(P>0.05);AAV注射后,AAV组和FBN2注射组FBN2 基因的蛋白的表达降低(P<0.05)。FBN2蛋白注射3次后,FBN2注射组与正常对照组相比,视网膜的FBN2基因的蛋白表达稍低(P>0.05));与AAV 组相比视网膜的FBN2基因的蛋白表达显著升高(P<0.05)。
本说明书中未作详细描述的内容属于本领域专业技术人员公知的现有技术。以上所述仅为本申请的实施例而已,并不用于限制本申请。对于本领域技术人员来说,本申请可以有各种更改和变化。凡在本申请的精神和原理之内所作的任何修改、等同替换、改进等,均应包含在本申请的权利要求范围之内。
Claims (10)
1.原纤维蛋白-2重组蛋白在制备预防或治疗原纤维蛋白-2缺陷型眼病的产品中的用途。
2.根据权利要求1所述的用途,其特征在于,所述原纤维蛋白-2缺陷型眼病选自遗传性视网膜病变、轴性近视和先天性黄斑变性中的至少一种。
3.根据权利要求1或2所述的用途,其特征在于,所述产品为药物、试剂或疫苗。
4.原纤维蛋白-2重组蛋白在非治疗目的减少视网膜渗出及眼底沉积物的用途。
5.原纤维蛋白-2重组蛋白在非治疗目的调控视网膜电图波形振幅的用途;
优选的,所述调控视网膜电图波形振幅为将视网膜电图波形振幅恢复至正常;
优选的,所述视网膜电图波形振幅选自暗适应视杆细胞反应波形振幅、暗适应最大混合反应波形振幅、暗适应震荡电位反应波形振幅和明适应视锥细胞反应波形振幅中至少一种。
6.原纤维蛋白-2重组蛋白在非治疗目的增加视网膜外核层厚度的用途;
原纤维蛋白-2重组蛋白在非治疗目的降低眼轴长度的用途。
7.原纤维蛋白-2重组蛋白在非治疗目的提高原纤维蛋白-2的表达的用途;
优选的,所述原纤维蛋白-2的表达选自原纤维蛋白-2基因的表达或原纤维蛋白-2蛋白的表达;
优选的,所述原纤维蛋白-2基因的表达为原纤维蛋白-2基因mRNA的表达。
8.一种预防或治疗原纤维蛋白-2缺陷型眼病的产品,其特征在于,所述产品是以原纤维蛋白-2重组蛋白作为唯一活性成分,或包含原纤维蛋白-2重组蛋白的组合物。
9.根据权利要求8所述的产品,其特征在于,所述产品为药物,所述组合物还包括药用辅料;
优选的,所述药用辅料选自稀释剂、赋形剂、香味剂和甜味剂中的至少一种;
优选的,所述药物的制剂是混悬剂、乳剂、溶液剂、糖浆剂或注射剂中的至少一种;
优选的,所述药物的给药方式为滴注或注射;
优选的,所述药物的给药方式为玻璃体腔注射。
10.根据权利要求8或9所述的产品,其特征在于,所述产品中原纤维蛋白-2重组蛋白的含量为0.01~5.0μg/μL;
优选的,所述产品中原纤维蛋白-2重组蛋白的含量为0.1~1.0μg/μL;
优选的,所述产品中原纤维蛋白-2重组蛋白的含量为0.2~0.5μg/μL。
Priority Applications (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202110969727.0A CN115227806A (zh) | 2021-08-23 | 2021-08-23 | 原纤维蛋白-2重组蛋白在制备预防或治疗原纤维蛋白-2缺陷型眼病的产品中的用途 |
PCT/CN2021/115997 WO2023024134A1 (zh) | 2021-08-23 | 2021-09-01 | 原纤维蛋白-2重组蛋白在制备预防或治疗原纤维蛋白-2缺陷型眼病的产品中的用途 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202110969727.0A CN115227806A (zh) | 2021-08-23 | 2021-08-23 | 原纤维蛋白-2重组蛋白在制备预防或治疗原纤维蛋白-2缺陷型眼病的产品中的用途 |
Publications (1)
Publication Number | Publication Date |
---|---|
CN115227806A true CN115227806A (zh) | 2022-10-25 |
Family
ID=83666152
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202110969727.0A Pending CN115227806A (zh) | 2021-08-23 | 2021-08-23 | 原纤维蛋白-2重组蛋白在制备预防或治疗原纤维蛋白-2缺陷型眼病的产品中的用途 |
Country Status (2)
Country | Link |
---|---|
CN (1) | CN115227806A (zh) |
WO (1) | WO2023024134A1 (zh) |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN102978284A (zh) * | 2012-11-19 | 2013-03-20 | 金子兵 | 一种筛查各类眼科遗传性疾病的基因芯片及其制备和使用方法 |
US20180023094A1 (en) * | 2014-10-21 | 2018-01-25 | University Of Massachusetts | Recombinant aav variants and uses thereof |
CN109679962A (zh) * | 2018-12-05 | 2019-04-26 | 广州派真生物技术有限公司 | Fbn2基因及其应用 |
CN112274631A (zh) * | 2020-09-28 | 2021-01-29 | 南京医科大学 | 重组蛋白Semaphorin3G在防治视网膜疾病中的医药用途 |
Family Cites Families (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101204579B (zh) * | 2006-12-14 | 2011-07-27 | 复旦大学 | 重组人微小纤溶酶原在制备防、治眼科疾病药物中的应用 |
-
2021
- 2021-08-23 CN CN202110969727.0A patent/CN115227806A/zh active Pending
- 2021-09-01 WO PCT/CN2021/115997 patent/WO2023024134A1/zh active Application Filing
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN102978284A (zh) * | 2012-11-19 | 2013-03-20 | 金子兵 | 一种筛查各类眼科遗传性疾病的基因芯片及其制备和使用方法 |
US20180023094A1 (en) * | 2014-10-21 | 2018-01-25 | University Of Massachusetts | Recombinant aav variants and uses thereof |
CN109679962A (zh) * | 2018-12-05 | 2019-04-26 | 广州派真生物技术有限公司 | Fbn2基因及其应用 |
CN112274631A (zh) * | 2020-09-28 | 2021-01-29 | 南京医科大学 | 重组蛋白Semaphorin3G在防治视网膜疾病中的医药用途 |
Non-Patent Citations (3)
Title |
---|
RINKI RATNAPRIYA等: "Rare and common variants in extracellular matrix gene Fibrillin 2 (FBN2) are associated with macular degeneration", 《HUMAN MOLECULAR GENETICS》 * |
YANRONG SHI等: "Ocular phenotype of Fbn2-null mice", 《INVEST OPHTHALMOL VIS SCI》 * |
徐福如等: "FBN2基因突变与遗传性结缔组织病的发生", 《遗传》 * |
Also Published As
Publication number | Publication date |
---|---|
WO2023024134A1 (zh) | 2023-03-02 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Mao et al. | Long-term rescue of retinal structure and function by rhodopsin RNA replacement with a single adeno-associated viral vector in P23H RHO transgenic mice | |
CN105209619B (zh) | miR-204和miR-211及其用途 | |
JP2019205465A (ja) | 錐体細胞における増強された遺伝子発現のための組成物および方法 | |
JP7097398B2 (ja) | ミオシリン(myoc)緑内障を処置するためのアデノ随伴ウイルスベクター | |
IL254148B (en) | Preparations and methods for intraocular delivery of polynucleotides to the retina | |
TW202228646A (zh) | 諸如凝膠調配物之用於脈絡膜上投與之調配物 | |
TW202228649A (zh) | 諸如形成聚集體之調配物之用於脈絡膜上投與之調配物 | |
TW202228648A (zh) | 諸如高黏度調配物之用於脈絡膜上投與之調配物 | |
JP2021520232A (ja) | 黄斑ジストロフィーを処置するための組成物及び方法 | |
JP2024119830A (ja) | ベスト病の処置のためのアデノ随伴ウイルスベクター | |
Bennett et al. | Gene delivery to the retina: from mouse to man | |
US20240050527A1 (en) | METHODS OF TREATING AGE-RELATED MACULAR DISEASES USING AIMP2-DX2 AND OPTIONALLY A TARGET SEQUENCE FOR miR-142 AND COMPOSITIONS THEREOF | |
CN115227806A (zh) | 原纤维蛋白-2重组蛋白在制备预防或治疗原纤维蛋白-2缺陷型眼病的产品中的用途 | |
CN111705069A (zh) | 一种多神经营养因子联合表达载体及其应用 | |
Fan et al. | MicroRNA-126 inhibits pathological retinal neovascularization via suppressing vascular endothelial growth factor expression in a rat model of retinopathy of prematurity | |
JP2023544803A (ja) | Cln2疾患の眼症状に対する遺伝子療法 | |
KR20180109278A (ko) | 종간 교차활성을 지닌 mTOR를 표적으로 하는 siRNA를 함유하는 망막혈관질환 치료용 조성물 | |
CA3130817A1 (en) | Method for the treatment of a disease using pigment epithelium-derived factor (pedf) | |
CN108721315A (zh) | 小分子核酸miR-21在治疗青光眼中的应用 | |
WO2023078099A1 (zh) | 一种用于治疗神经损伤疾病的基因药物 | |
US20220331241A1 (en) | Treatment of x-linked juvenile retinoschisis | |
US20230062110A1 (en) | Intravitreal dosing for delivery of polynucleotides to retinal cones | |
CN116635004A (zh) | 用于脉络膜上施用的制剂如凝胶制剂 | |
CN118078960A (zh) | 一种多肽在制备青光眼治疗药物中的应用 | |
Chern | The Development of a Prostaglandin-Based Gene Therapy for the Treatment of Glaucoma |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
CB02 | Change of applicant information |
Country or region after: China Address after: 250002 No. 48, heroic mountain road, Ji'nan, Shandong Applicant after: The affiliated ophthalmology hospital of Shandong University of Traditional Chinese Medicine Address before: 250002 No. 48, heroic mountain road, Ji'nan, Shandong Applicant before: Affiliated Eye Hospital of Shandong University of Traditional Chinese Medicine (Shandong Shierming Eye Hospital) Country or region before: China |
|
CB02 | Change of applicant information |